AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03335020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-D Volume Ultrasound
Description: When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
Study NCT03335020 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 3-D Volume Ultrasound
Description: When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
Study NCT01566799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500 mg/day po for 24 weeks.
Study NCT02981797 — intervention group
Intervention type: OTHER
Intervention: Blood Collection During Standard of Care Treatment
Description: Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
Study NCT01178983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surface electromyography
Description: Surface electromyography (SEMG) telebiofeedback
Study NCT01178983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyography
Description: conventional biofeedback
Study NCT04376723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Mobile Application
Description: Mobile phones will not be provided to participants, but app subscriptions will be provided.
Study NCT00190307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 75 mg/day
Description: aspirin 75 mg/day
Study NCT01815268 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD Vaccine
Description: Nursing home residents are allocated to receive standard-dose vaccine.
Study NCT02179892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
Study NCT02179892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: Oral acetaminophen 650 mg every 6 hours.
Study NCT04513444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation with music listening and medical hypnosis during radiotherapy treatment:
Description: * Music listening (According to the patient's wishes),~* Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~* Self-hypnosis during the 4th and 5th radiotherapy session,~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.
Study NCT04513444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation with music listening during radiotherapy treatment:
Description: * Music listening (According to the patient's wishes),~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.
Study NCT04968535 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimaWELL
Description: mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
Study NCT04968535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimaWELL
Description: mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
Study NCT00256412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Description: Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
Study NCT00256412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo each day
Study NCT01027520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of coban dressing
Description: application of a intraoperative coban dressing with reapplications following dressing removal.
Study NCT03798028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.
Study NCT02830503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feeding tube daily replacement
Description: Feeding tubes replaced once a day in the first week of life.
Study NCT02119403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: There are no other inteventions.
Description: This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
Study NCT02104674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: Given SC on Days 1, 29, and 57
Study NCT02104674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast [Singulair]
Description: 10 mg given orally once daily for 12 weeks
Study NCT02104674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SC injection given on Days 1, 29, and 57
Study NCT05030883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source of news
Description: The main intervention was the source of the news that was shown to participants
Study NCT01961219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation Under Anesthesia
Description: Closed manipulation under anesthesia.
Study NCT01961219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic capsular release
Description: Arthroscopic capsular release
Study NCT03806114 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior Approach Precautions
Description: These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
Study NCT03806114 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior Approach Precautions
Description: These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
Study NCT03806114 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Precautions
Description: For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
Study NCT01815268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Free Vaccine
Description: Nursing home facilities are provided free standard-dose vaccine for their staff.
Study NCT01815268 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Free Vaccine
Description: Nursing home facilities are provided free standard-dose vaccine for their staff.
Study NCT01815268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
Study NCT01815268 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
Study NCT02943603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFLOFOX6 + pembrolizumab
Description: the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
Study NCT03200938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: formocresol and zinc oxide.
Description: Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
Study NCT03200938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBS CIMMO cement.
Description: Removal of the coronary pulp from primary molar teeth, use of PBS cement
Study NCT04111081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular pressure
Description: Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
Study NCT04111081 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shame auricular pressure
Description: Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
Study NCT02451800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in-class yoga
Description: In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
Study NCT02451800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga by DVD
Description: Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
Study NCT02451800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching by DVD
Description: Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
Study NCT02148250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 100 syringe units
Description: Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Study NCT02148250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 200 syringe units
Description: Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Study NCT03197792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All patients
Description: TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death.
Study NCT00426504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
Study NCT03223363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2D and 3D ultrasonography
Description: All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
Study NCT03223363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2D and 3D ultrasonography
Description: All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
Study NCT02186119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
Study NCT02186119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
Study NCT02186119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at the visits noted per protocol.
Study NCT02485470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPACT
Description: Maintaining Physical Activity during Cancer Treatment
Study NCT01876719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08
Study NCT01876719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02592434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tofacitinib)
Description: During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects >=40 kg.
Study NCT02592434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet or solution for tofacitinib
Study NCT01725087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT01725087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose GRT6005
Study NCT01725087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose GRT6005
Study NCT01725087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose GRT6005
Study NCT01725087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Study NCT02509754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation catheter ablation
Study NCT02509754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Composite of optimal medical therapy and device implantation
Study NCT01747616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)
Description: 1 drop of the medical device in 1 randomly chosen eye
Study NCT02500017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg rapid release melatonin capsule
Study NCT02500017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study NCT04352842 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
Study NCT00794326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Peritoneal Dialysis
Description: Treatment with one bag per day during 6 months
Study NCT00794326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution for Peritoneal Dialysis
Description: Treatment with one bag per day during 6 months
Study NCT04214951 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: Patients will be given eltrombopag 50mg once daily for 6 weeks.
Study NCT04023695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid with lidocaine with epinephrine
Description: Trigger finger injection
Study NCT04214951 — intervention group
Intervention type: DRUG
Intervention: Recombinant human thrombopoietin (rh-TPO)
Description: Patients will be given rh-TPO 300 U/kg once daily for 21 days.
Study NCT00443352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
Study NCT03492073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Supportive Mindfulness-based Program
Description: Mindfulness training
Study NCT03492073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional Supportive Program
Description: Narrative-orientated therapy.
Study NCT04777773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dual-task training
Description: dual-task training
Study NCT01986842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein diet
Description: Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
Study NCT01093859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-105
Description: Sterile solution for intravenous injection
Study NCT03754816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS II and parasternal block
Description: 10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
Study NCT03754816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine
Study NCT03492983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 10 g/day of high cocoa content chocolate for six months.
Study NCT04111237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two Finger technique
Description: two finger method for chest compression provuision
Study NCT04111237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Two Thumb Technique
Description: Two thumb technique
Study NCT00545233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms subcutaneous weekly for 48 weeks
Study NCT00545233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms subcutaneous weekly for 48 weeks
Study NCT00545233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000-1600 mg day orally for 48 weeks.
Study NCT00545233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1600 mg day orally for 48 weeks.
Study NCT00545233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
Study NCT01075620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC-Sigma RP
Description: Posterior stabilizing rotating platform total knee components
Study NCT01075620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LPS RP
Description: non-posterior stabilized rotating platform design
Study NCT00728559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacain 0.5%
Description: trocar site injection
Study NCT04023695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid with normal saline
Description: Trigger finger injection